{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:24:22Z","timestamp":1790958262848,"version":"4.1.0"},"reference-count":262,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ad.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:05:20Z","timestamp":1748430320000},"page":"T703-T730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["[Translated article] Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS)"],"prefix":"10.1016","volume":"116","author":[{"given":"M.","family":"Ribera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dauden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"De La Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.05.010_bib1000","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000512930","article-title":"Topical treatment of psoriasis vulgaris: the Swiss treatment pathway","volume":"237","author":"Maul","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bjd.12393","article-title":"Topical treatments for chronic plaque psoriasis of the scalp: a systematic review","volume":"169","author":"Mason","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0001-7310(09)70534-4","article-title":"[Update of the topical treatment of psoriasis]","volume":"100","author":"Carrascosa","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.010_bib1020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.010_bib1025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.010_bib1030","first-page":"Cd011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2025.05.010_bib1035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","article-title":"Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey","volume":"12","author":"Lebwohl","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl. 3","key":"10.1016\/j.ad.2025.05.010_bib1040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-3083.2012.04525.x","article-title":"Adherence to topical treatment in psoriasis: a systematic literature review","volume":"26","author":"Devaux","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/09546634.2016.1178375","article-title":"Medical adherence to topical corticosteroid preparations prescribed for psoriasis: a systematic review","volume":"28","author":"Svendsen","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjd.12039","article-title":"Adherence to medication in patients with psoriasis: a systematic literature review","volume":"168","author":"Thorneloe","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000444581","article-title":"Patient adherence to biologic agents in psoriasis","volume":"232","author":"Hsu","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1060","article-title":"A new classification of the severity of psoriasis: what's moderate psoriasis?","volume":"11","author":"Salgado-Boquete","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ad.2025.05.010_bib1065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaad.2013.06.027","article-title":"Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review","volume":"69","author":"Mason","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.12276","article-title":"Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses","volume":"168","author":"Samarasekera","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1075","series-title":"Uso adecuado de los corticoides t\u00f3picos dermatol\u00f3gicos","year":"2017"},{"key":"10.1016\/j.ad.2025.05.010_bib1080","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.14811","article-title":"Topical treatments for scalp psoriasis: summary of a cochrane systematic review","volume":"176","author":"Schlager","year":"2017","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2025.05.010_bib1085","first-page":"e6981","article-title":"\u00bfCorticoides t\u00f3picos o an\u00e1logos de vitamina D para la psoriasis en placa?","volume":"16","author":"Venegas-Iribarren","year":"2016","journal-title":"Medwave"},{"key":"10.1016\/j.ad.2025.05.010_bib1090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/120347540300700301","article-title":"The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions","volume":"7","author":"Gottlieb","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2025.05.010_bib1095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-4362.2002.01431.x","article-title":"A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis","volume":"41","author":"Lebwohl","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1100","first-page":"835","article-title":"Desoximetasone 0.25% spray for the relief of scaling in adults with plaque psoriasis","volume":"14","author":"Keegan","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/120347540100500404","article-title":"Betamethasone valerate foam for treatment of nonscalp psoriasis","volume":"5","author":"Stein","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"Suppl.","key":"10.1016\/j.ad.2025.05.010_bib1110","first-page":"2","article-title":"A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis","volume":"67","author":"James","year":"2001","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.010_bib1115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1684\/ejd.2010.0948","article-title":"Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study","volume":"20","author":"Fleming","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000066440","article-title":"A new calcipotriol\/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris","volume":"205","author":"Kaufmann","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2008.04.027","article-title":"A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial","volume":"59","author":"Jemec","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1130","first-page":"1997","article-title":"A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand","volume":"90","author":"Thawornchaisit","year":"2007","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.ad.2025.05.010_bib1135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mjd.2003.130","article-title":"Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis","volume":"48","author":"Papp","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09546630510041060","article-title":"Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis","volume":"16","author":"Lowe","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/09546630305545","article-title":"Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy","volume":"14","author":"Camarasa","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1150","first-page":"52","article-title":"Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis","volume":"8","author":"Menter","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1155","first-page":"357","article-title":"An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis","volume":"5","author":"Beutner","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1160","first-page":"28","article-title":"A randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of ammonium lactate lotion 12% and halobetasol propionate ointment 0.05% in the treatment and maintenance of psoriasis","volume":"4","author":"Emer","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1165","first-page":"201","article-title":"An open-label, multicenter study of the efficacy and safety of a weekday\/weekend treatment regimen with calcitriol ointment 3 microg\/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis","volume":"88","author":"Hudson","year":"2011","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.010_bib1170","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1365-2133.2006.07236.x","article-title":"A 52-week randomized safety study of a calcipotriol\/betamethasone dipropionate two-compound product (Dovobet\/Daivobet\/Taclonex) in the treatment of psoriasis vulgaris","volume":"154","author":"Kragballe","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000096069","article-title":"Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol\/betamethasone dipropionate two-compound product (daivobet\/dovobet\/taclonex) in the treatment of psoriasis vulgaris","volume":"213","author":"Kragballe","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1180","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/0019-5154.139872","article-title":"Topical steroid-damaged skin","volume":"59","author":"Abraham","year":"2014","journal-title":"Indian J Dermatol"},{"issue":"Suppl. 3","key":"10.1016\/j.ad.2025.05.010_bib1185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1468-3083.2012.04523.x","article-title":"Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy","volume":"26","author":"Castela","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2025.05.010_bib1190","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1346-8138.2011.01487.x","article-title":"Femoral head osteonecrosis after long-term topical corticosteroid treatment in a psoriasis patient","volume":"39","author":"Takahashi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1195","first-page":"233","article-title":"Femoral head osteonecrosis after topical corticosteroid therapy","volume":"19","author":"El Maghraoui","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1442-9071.2004.00787.x","article-title":"Glaucoma from topical corticosteroids to the eyelids","volume":"32","author":"Garrott","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ad.2025.05.010_bib1205","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2337\/dc18-2158","article-title":"Association between topical corticosteroid use and type 2 diabetes in two european population-based adult cohorts","volume":"42","author":"Andersen","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ad.2025.05.010_bib1210","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaad.2020.09.037","article-title":"Twice-weekly topical calcipotriene\/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1215","doi-asserted-by":"crossref","first-page":"436","DOI":"10.36849\/JDD.5728","article-title":"Four-week daily calcipotriene\/betamethasone dipropionate foam is highly efficacious in patients with psoriasis (PSO-LONG Lead-in Phase)","volume":"20","author":"Warren","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1220","first-page":"1468","article-title":"Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris \u2013 a randomized Phase III Study (PSO-FAST)","volume":"14","author":"Leonardi","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1225","first-page":"981","article-title":"The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health-related quality of life in patients with psoriasis vulgaris: results from the randomized PSO-FAST Study","volume":"15","author":"Leonardi","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40257-017-0258-0","article-title":"Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE Study","volume":"18","author":"Paul","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1468-3083.2005.01343.x","article-title":"Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis","volume":"20","author":"Kragballe","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1240","first-page":"242","article-title":"Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene\/betamethasone dipropionate cream versus suspension\/gel","volume":"21","author":"Armstrong","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2025.05.010_bib1245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jdv.18755","article-title":"A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: direct and indirect evidence from phase 3 trials discussed at the 30(th) EADV Congress 2021","volume":"37","author":"Pinter","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1250","doi-asserted-by":"crossref","first-page":"420","DOI":"10.36849\/JDD.5653","article-title":"A phase 3 randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream","volume":"20","author":"Stein Gold","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1255","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jdv.17734","article-title":"A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis","volume":"36","author":"Pinter","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1260","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1684\/ejd.2018.3302","article-title":"Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study","volume":"28","author":"Griffiths","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1265","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/09546634.2015.1083935","article-title":"Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris \u2013 a randomized phase II study","volume":"27","author":"Koo","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1270","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jdv.15398","article-title":"Rapid onset of action of calcipotriol\/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease","volume":"33","author":"Pink","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1275","first-page":"119","article-title":"Fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with psoriasis vulgaris: pooled data from three randomized controlled studies","volume":"15","author":"Menter","year":"2017","journal-title":"Skinmed"},{"key":"10.1016\/j.ad.2025.05.010_bib1280","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/1346-8138.15806","article-title":"Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis","volume":"48","author":"Zhao","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1285","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/bmj.320.7240.963","article-title":"Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis","volume":"320","author":"Ashcroft","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ad.2025.05.010_bib1290","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2340\/0001555577228230","article-title":"A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 micrograms\/g) and calcipotriol (50 micrograms\/g) in the treatment of chronic plaque psoriasis vulgaris","volume":"77","author":"Bourke","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1295","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2133.1997.tb03790.x","article-title":"Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. a double-blind trial","volume":"137","author":"Veien","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1300","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000323408","article-title":"Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial","volume":"222","author":"Langley","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ijd.12788","article-title":"Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population","volume":"55","author":"Ma","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1310","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1365-2133.2002.04967.x","article-title":"Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial","volume":"147","author":"Guenther","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11630710-000000000-00000","article-title":"Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of 2multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials","volume":"13","author":"Feldman","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1320","first-page":"275","article-title":"Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream","volume":"11","author":"Alora-Palli","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000018457","article-title":"The efficacy, safety and tolerance of calcitriol 3 microg\/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol","volume":"201","author":"Hutchinson","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1330","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2133.1998.02461.x","article-title":"Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy","volume":"139","author":"Kragballe","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1335","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.1996.tb07608.x","article-title":"Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis","volume":"134","author":"P\u00e8rez","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1365-4362.2001.01067-7.x","article-title":"Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments","volume":"40","author":"Lebwohl","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1345","first-page":"855","article-title":"Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies","volume":"17","author":"Sugarman","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1350","first-page":"1012","article-title":"Efficacy safety, and tolerability of a halobetasol 0.01%\/tazarotene 0.045% fixed combination in the treatment of severe localized plaque psoriasis: Post hoc analysis of two phase iii randomized controlled trials","volume":"18","author":"Lebwohl","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archderm.134.1.57","article-title":"The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis","volume":"134","author":"Krueger","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1360","first-page":"355","article-title":"Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study","volume":"68","author":"Scher","year":"2001","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.010_bib1365","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-4362.2001.01167.x","article-title":"Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis","volume":"40","author":"Koo","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1370","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/0378-6323.44302","article-title":"Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis","volume":"74","author":"Kaur","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2025.05.010_bib1375","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2230.2009.03610.x","article-title":"Topical tazarotene vs. coal tar in stable plaque psoriasis","volume":"35","author":"Kumar","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1380","first-page":"41","article-title":"Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study","volume":"63","author":"Poulin","year":"1999","journal-title":"Cutis"},{"issue":"Pt 3","key":"10.1016\/j.ad.2025.05.010_bib1385","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0190-9622(97)80397-0","article-title":"Clinical safety of tazarotene in the treatment of plaque psoriasis","volume":"37","author":"Marks","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl.","key":"10.1016\/j.ad.2025.05.010_bib1390","first-page":"4","article-title":"An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and\/or corticosteroid","volume":"66","author":"Tanghetti","year":"2000","journal-title":"Cutis"},{"issue":"Pt 3","key":"10.1016\/j.ad.2025.05.010_bib1395","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0190-9622(97)80395-7","article-title":"Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis","volume":"37","author":"Chandraratna","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1400","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0149-2918(98)80091-X","article-title":"Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study","volume":"20","author":"Koo","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1405","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.141.1.43","article-title":"Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment","volume":"141","author":"Carroll","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1410","first-page":"855","article-title":"A double-blind, randomized clinical trial of 20% alpha\/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis","volume":"12","author":"Akamine","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1415","first-page":"270","article-title":"Salicylic acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis","volume":"10","author":"Kircik","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1420","first-page":"868","article-title":"Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis","volume":"12","author":"Singh","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/09546639809160546","article-title":"A comparison of the efficacy and safety of the combination mometasone furoate 0.1%\/salicylic acid 5% ointment with each of its components in psoriasis","volume":"9","author":"Katz","year":"1998","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1430","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0149-2918(97)80094-X","article-title":"Mometasone furoate 0.1%\u2013salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis","volume":"19","author":"Medansky","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1435","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/095466300300165192","article-title":"Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar\/1% coconut oil\/0.5% salicylic acid (Capasal) shampoo and long-term experience","volume":"11","author":"McKinnon","year":"2000","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1440","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-4362.1997.00176.x","article-title":"Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?","volume":"36","author":"Kumar","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1445","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00128071-200405020-00001","article-title":"Fixed-dose combination therapy for psoriasis","volume":"5","author":"Guenther","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1450","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2340\/00015555713740","article-title":"Topical salicylic acid interferes with UVB therapy for psoriasis","volume":"71","author":"Kristensen","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1455","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/archderm.142.9.1138","article-title":"1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study","volume":"142","author":"Kreuter","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1460","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archderm.134.9.1101","article-title":"Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study","volume":"134","author":"Zonneveld","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1465","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2004.06.010","article-title":"Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study","volume":"51","author":"Gribetz","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1470","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaad.2004.07.011","article-title":"Tacrolimus ointment is effective for facial and intertriginous psoriasis","volume":"51","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1475","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1365-2133.2007.08201.x","article-title":"Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(\u22121) ointment and tacrolimus 0.3 mg g(\u22121) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial","volume":"157","author":"Liao","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1480","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5114\/ada.2019.91425","article-title":"Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials","volume":"36","author":"Ab\u0119d\u017a","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.ad.2025.05.010_bib1485","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/09546630701646156","article-title":"Efficacy, safety and quality of life of calcipotriol\/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial","volume":"18","author":"Saraceno","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1490","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00128071-200607030-00004","article-title":"Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene\/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial","volume":"7","author":"White","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1495","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000086444","article-title":"Cost-effectiveness of once-daily treatment with calcipotriol\/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris","volume":"211","author":"Peeters","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1500","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/00015550252948194","article-title":"A new calcipotriol\/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris","volume":"82","author":"Douglas","year":"2002","journal-title":"Acta Derm Venereol"},{"issue":"Pt 1","key":"10.1016\/j.ad.2025.05.010_bib1505","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mjd.2000.105167","article-title":"Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks","volume":"43","author":"Singh","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1510","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2133.1998.02070.x","article-title":"Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks\u2019 treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study","volume":"138","author":"Ruzicka","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1515","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-2133.2004.05986.x","article-title":"Efficacy of once-daily treatment regimens with calcipotriol\/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris","volume":"150","author":"Kragballe","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1520","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1365-4632.2010.04598.x","article-title":"A calcipotriene\/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic\/Latino and Black\/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial","volume":"49","author":"Tyring","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1525","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000080854","article-title":"Efficacy of treatment with calcipotriol\/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial","volume":"209","author":"Ortonne","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1530","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000130425","article-title":"Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study","volume":"217","author":"Buckley","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1535","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2133.2009.09116.x","article-title":"Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial","volume":"161","author":"Kragballe","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1540","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2008.08927.x","article-title":"A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: A randomized, double-blind, controlled trial","volume":"160","author":"van de Kerkhof","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1545","first-page":"109","article-title":"A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis","volume":"39","author":"Y\u0131lmaz","year":"2005","journal-title":"Turkderm-Turk Arch Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1550","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000155642","article-title":"A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis","volume":"217","author":"Luger","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1555","first-page":"92","article-title":"Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial","volume":"12","author":"Menter","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1560","first-page":"252","article-title":"A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp","volume":"1","author":"Fredriksson","year":"1976","journal-title":"Pharmatherapeutica"},{"key":"10.1016\/j.ad.2025.05.010_bib1565","first-page":"351","article-title":"Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis","volume":"3","author":"Frappaz","year":"1993","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1570","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2133.1994.tb06887.x","article-title":"Calcipotriol improves the response of psoriasis to PUVA","volume":"130","author":"Speight","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1575","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000247926","article-title":"Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris","volume":"181","author":"Kragballe","year":"1990","journal-title":"Dermatologica"},{"key":"10.1016\/j.ad.2025.05.010_bib1580","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000018151","article-title":"Topical calcipotriol combined with phototherapy for psoriasis. The results of 2 randomized trials and a review of the literatura. Calcipotriol-UVB Study Group","volume":"198","author":"Molin","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1585","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000018309","article-title":"Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group","volume":"200","author":"Ramsay","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1590","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archderm.1995.01690230085013","article-title":"Photosensitivity associated with combined UV-B and calcipotriene therapy","volume":"131","author":"McKenna","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1595","first-page":"2844","article-title":"Self-control study of combination treatment of 308nm excimer laser and calcipotriene ointment on stable psoriasis vulgaris","volume":"7","author":"Tang","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ad.2025.05.010_bib1600","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-4632.2011.05257.x","article-title":"Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis","volume":"51","author":"Ozkan","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1605","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1365-2133.2003.05380.x","article-title":"Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial","volume":"149","author":"Woo","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1610","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0190-9622(99)70259-8","article-title":"No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis","volume":"41","author":"Brands","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"Pt 1","key":"10.1016\/j.ad.2025.05.010_bib1615","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2000.107940","article-title":"Tazarotene plus UVB phototherapy in the treatment of psoriasis","volume":"43","author":"Koo","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1620","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2230.2011.04061.x","article-title":"Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis","volume":"36","author":"Khandpur","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1625","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s13555-022-00792-0","article-title":"Pretreatment with an aerosol foam containing calcipotriene and betamethasone strongly improves the efficacy of narrow-band UVB phototherapy","volume":"12","author":"Licata","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.05.010_bib1630","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000018026","article-title":"Scalp psoriasis, clinical presentations and therapeutic management","volume":"197","author":"Van de Kerkhof","year":"1998","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1635","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2133.2003.05173.x","article-title":"The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial","volume":"148","author":"de Jong","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1640","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0190-9622(94)70138-5","article-title":"A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study","volume":"31","author":"Grossman","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1645","doi-asserted-by":"crossref","DOI":"10.3109\/09546634.2011.565017","article-title":"Combined treatment with low-dose cyclosporine and calcipotriol\/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study","volume":"23","author":"Vena","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1650","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2013.03.031","article-title":"A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis","volume":"69","author":"Lebwohl","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1655","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2133.2010.09791.x","article-title":"A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol\/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study","volume":"163","author":"Tha\u00e7i","year":"2010","journal-title":"Br J Dermatol"},{"issue":"Suppl.","key":"10.1016\/j.ad.2025.05.010_bib1660","article-title":"Efects of adalimumab monotherapy versus adalimumab plus betamethasone\/calcipotriol on patient-reported outcomes in patients with palmoplantar, nail, or scalp psoriasis","volume":"62","author":"Thaci","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1665","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jdv.12058","article-title":"Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review","volume":"27","author":"Hendriks","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1670","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0378-6323.175919","article-title":"Topical calcipotriol\/betamethasone dipropionate for psoriasis vulgaris: a systematic review","volume":"82","author":"Yan","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2025.05.010_bib1675","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/09546634.2017.1328098","article-title":"Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis","volume":"28","author":"Koo","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1680","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jaad.2006.05.026","article-title":"A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes","volume":"55","author":"Koo","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1685","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0190-9622(98)70323-8","article-title":"Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2025.05.010_bib1690","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jdv.12444","article-title":"Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp","volume":"28","author":"Kragballe","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1695","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1468-3083.2012.04640.x","article-title":"Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review","volume":"27","author":"Hendriks","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1700","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/030006058201000606","article-title":"Comparison of betamethasone dipropionate lotion with salicylic acid (diprosalic\u00ae) and clobetasol propionate lotion (Dermovate\u00ae) in the treatment of psoriasis of the scalp","volume":"10","author":"Hillstr\u00f6m","year":"1982","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ad.2025.05.010_bib1705","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-4362.1999.00500.x","article-title":"The role of salicylic acid in the treatment of psoriasis","volume":"38","author":"Lebwohl","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1710","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/030006058301100208","article-title":"Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses","volume":"11","author":"Elie","year":"1983","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ad.2025.05.010_bib1715","first-page":"815","article-title":"Halobetasol 0.01%\/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy","volume":"18","author":"Stein Gold","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1720","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/120347540200600201","article-title":"A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis","volume":"6","author":"Green","year":"2002","journal-title":"J Cutan Med Surg"},{"issue":"Pt 1","key":"10.1016\/j.ad.2025.05.010_bib1725","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0190-9622(98)70008-8","article-title":"Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 54","key":"10.1016\/j.ad.2025.05.010_bib1730","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2133.1999.140S54018.x","article-title":"Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis","volume":"140","author":"Gollnick","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1735","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0149-2918(00)83065-9","article-title":"A comparison of tazarotene 0.1% gel 11daily plus mometasone furoate 0.1% cream 11daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis","volume":"22","author":"Guenther","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1740","doi-asserted-by":"crossref","first-page":"814","DOI":"10.5414\/CPP48814","article-title":"Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography","volume":"48","author":"Buder","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1745","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1067\/mjd.2002.120453","article-title":"Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study","volume":"46","author":"Bowman","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1750","first-page":"140","article-title":"Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis","volume":"90","author":"Tirado-S\u00e1nchez","year":"2012","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.010_bib1755","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000088507","article-title":"Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments","volume":"211","author":"Brill","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib1760","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/09546634.2018.1529386","article-title":"The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and\/or biologic treatment","volume":"30","author":"Wu","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1765","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CEOR.S126975","article-title":"Topical medication utilization and health resources consumption in adult patients affected by psoriasis: Findings from the analysis of administrative databases of local health units","volume":"9","author":"Perrone","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ad.2025.05.010_bib1770","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000247698","article-title":"Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen","volume":"183","author":"Katz","year":"1991","journal-title":"Dermatologica"},{"key":"10.1016\/j.ad.2025.05.010_bib1775","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/archderm.1987.01660340070022","article-title":"Betamethasone dipropionate in optimized vehicle Intermittent pulse dosing for extended maintenance treatment of psoriasis","volume":"123","author":"Katz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1780","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/jdv.13865","article-title":"Optimal maintenance treatment with calcipotriol\/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial","volume":"31","author":"Lee","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1785","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/09546634.2013.800182","article-title":"Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol\u00ae gel) in the treatment of scalp psoriasis: results from a study in 885 patients","volume":"25","author":"Saraceno","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1790","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bjd.15466","article-title":"A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol\/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1795","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1800","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/02656736.2011.647942","article-title":"Treatment of plaque-type psoriasis with the 308nm excimer laser in combination with dithranol or calcipotriol","volume":"28","author":"Rogalski","year":"2012","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ad.2025.05.010_bib1805","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2133.1998.02030.x","article-title":"The effect of addition of calcipotriol ointment (50 micrograms\/g) to acitretin therapy in psoriasis","volume":"138","author":"Van de Kerkhof","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1810","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jdv.12555","article-title":"A Randomized, blinded assessor study to evaluate the efficacy and safety of etanercept 50mg 11 weekly plus as needed topical agent vs. etanercept 50mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)","volume":"29","author":"Papp","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1815","first-page":"878","article-title":"Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial","volume":"10","author":"Kircik","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1820","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s13555-020-00454-z","article-title":"Adjunctive use of calcipotriene\/betamethasone dipropionate foam in a real-world setting curtails the cost of biologics without reducing efficacy in psoriasis","volume":"10","author":"Bagel","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.05.010_bib1825","doi-asserted-by":"crossref","first-page":"188","DOI":"10.36849\/JDD.2020.3989","article-title":"Management of residual psoriasis in patients on biologic treatment","volume":"19","author":"Haidari","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1830","first-page":"235","article-title":"Adjunctive use of calcipotriene 0.005%\/betamethasone dipropionate 0.064% foam in patients with psoriasis treated with ixekizumab","volume":"21","author":"Bagel","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1835","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jdv.12934","article-title":"Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE","volume":"29","author":"Papp","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1840","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11539780-000000000-00000","article-title":"Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study","volume":"12","author":"Naldi","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1845","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jdv.12270","article-title":"Betamethasone valerate dressing is non-inferior to calcipotriol\u2013betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial","volume":"28","author":"Ortonne","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1850","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546630152607862","article-title":"Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone","volume":"12","author":"Volden","year":"2001","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1855","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/00015550510042877","article-title":"Dovobet ointment under occlusion overnight for troublesome scalp psoriasis","volume":"86","author":"Downs","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1860","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2340\/00015555-0195","article-title":"Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study","volume":"87","author":"Rigopoulos","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1865","first-page":"59","article-title":"Occlusive versus nonocclusive calcipotriol ointment treatment for palmoplantar psoriasis","volume":"23","author":"Duweb","year":"2001","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.ad.2025.05.010_bib1870","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/09546639509097155","article-title":"Occlusive treatment of palmoplantar pustular psoriasis with clobetasol propionate ointment succeeded by short-term PUVA","volume":"6","author":"Nielsen","year":"1995","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1875","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2340\/0001555571540542","article-title":"A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis","volume":"71","author":"Kragballe","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1880","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1468-3083.2006.01387.x","article-title":"A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis","volume":"20","author":"Pacifico","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1885","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.1998.02554.x","article-title":"The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion","volume":"139","author":"Mrowietz","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1890","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1468-3083.2009.03221.x","article-title":"Quality of life in patients with scalp psoriasis treated with calcipotriol\/betamethasone dipropionate scalp formulation: a randomized controlled trial","volume":"23","author":"Ortonne","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1895","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/120347540100500502","article-title":"Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis","volume":"5","author":"Feldman","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2025.05.010_bib1900","first-page":"471","article-title":"A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp","volume":"46","author":"Ellis","year":"1989","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.ad.2025.05.010_bib1905","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0190-9622(91)70069-E","article-title":"A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis","volume":"24","author":"Olsen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1910","first-page":"885","article-title":"Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial","volume":"10","author":"Sofen","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1915","first-page":"571","article-title":"Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp","volume":"21","author":"Lepaw","year":"1978","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.010_bib1920","first-page":"367","article-title":"Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis","volume":"3","author":"Jarratt","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1925","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/09546630410023566","article-title":"Fluocinolone acetonide topical oil for scalp psoriasis","volume":"15","author":"Pauporte","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1930","first-page":"103","article-title":"Comparative studies of augmented betamethasone dipropionate lotion 0.05 percent and clobetasol propionate solution 0.05 percent correlation of the vasoconstriction assay and clinical activity in scalp psoriasis","volume":"8","author":"Jarratt","year":"1991","journal-title":"Ad Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1935","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0149-2918(95)80104-9","article-title":"Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis","volume":"17","author":"Katz","year":"1995","journal-title":"Clin Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1940","first-page":"145","article-title":"Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied 11daily vs. betamethasone valerate lotion 0.1% applied twice daily","volume":"15","author":"Van der Ploeg","year":"1989","journal-title":"Acta Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1945","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-4362.2000.00986-4.x","article-title":"Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery","volume":"39","author":"Franz","year":"2000","journal-title":"Int J Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2025.05.010_bib1950","first-page":"AB140","article-title":"Efficacy, safety results from a randomized, double-blind, vehicle-controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp","volume":"62","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1955","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jpag.2014.10.007","article-title":"Guttate psoriasis following streptococcal vulvovaginitis in a five-year-old girl","volume":"28","author":"Hernandez","year":"2015","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.ad.2025.05.010_bib1960","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2133.2006.07423.x","article-title":"Prospective aetiological study of diaper dermatitis in the elderly","volume":"155","author":"Foureur","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1965","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/09546639909056030","article-title":"Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation","volume":"10","author":"Baran","year":"1999","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib1970","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-4362.1999.00782.x","article-title":"Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy","volume":"38","author":"Franz","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib1975","first-page":"638","article-title":"A national double-blind clinical trial of a new corticosteroid lotion: a 12-investigator cooperative analysis","volume":"14","author":"Harris","year":"1972","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.ad.2025.05.010_bib1980","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/0926-9959(95)96175-8","article-title":"A randomized, single-blind study to compare hydrocortisone 17-butyrate 0.1% emulsion versus betamethasone 17, 21-dipropionate 0.05% lotion in the treatment of patients suffering from psoriasis of the scalp","volume":"5","author":"De Cuyper","year":"1995","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib1985","first-page":"198","article-title":"Hydrocortisone 17-butyrate 0.1% cream and fluocinolone acetonide 0.025% cream: a double-blind comparison in patients suffering from psoriasis of the scalp","volume":"29","author":"Gip","year":"1981","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.ad.2025.05.010_bib1990","first-page":"275","article-title":"Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis","volume":"8","author":"Willis","year":"1986","journal-title":"Clin Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib1995","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-4362.1989.tb02442.x","article-title":"Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis","volume":"28","author":"Swinehart","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2000","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/LGT.0b013e31824b9e5e","article-title":"Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature","volume":"16","author":"Kapila","year":"2012","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ad.2025.05.010_bib2005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2340\/00015555-1885","article-title":"Genital psoriasis awareness program: physical and psychological care for patients with genital psoriasis","volume":"95","author":"Meeuwis","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ped.12916","article-title":"Napkin psoriasis","volume":"58","author":"Afsar","year":"2016","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ad.2025.05.010_bib2015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000455021","article-title":"Psoriasiform diaper rash possibly induced by oral propranolol in an 18-month-old girl with infantile hemangioma","volume":"8","author":"Baggio","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2020","first-page":"333","article-title":"Psoriasis vulgaris of labium majus","volume":"38","author":"Weinrauch","year":"1986","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.010_bib2025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3928\/0090-4481-20060201-06","article-title":"An 18-month-old girl with chronic diaper dermatitis psoriasis presenting in the diaper area","volume":"35","author":"Greco","year":"2006","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.ad.2025.05.010_bib2030","first-page":"279","article-title":"Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis","volume":"88","author":"Tzung","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2133.1994.tb03382.x","article-title":"Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp","volume":"130","author":"Green","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2040","first-page":"300","article-title":"A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs. vehicle foam in the treatment of plaque-type psoriasis of the scalp","volume":"12","author":"Feldman","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2045","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.1994.tb04982.x","article-title":"Comparative effects of calcipotriol solution (50 micrograms\/ml) and betamethasone 17-valerate solution (1mg\/ml) in the treatment of scalp psoriasis","volume":"131","author":"Klaber","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09546630410024853","article-title":"Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis","volume":"16","author":"Reygagne","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib2055","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1468-3083.2004.01054.x","article-title":"Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream","volume":"18","author":"Amichai","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2060","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2230.2004.01505.x","article-title":"Psoriasis associated with vulval scarring","volume":"29","author":"Albert","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1365-2133.2003.05228.x","article-title":"Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(\u22121) ointment and calcipotriol 50 microg g(\u22121) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas","volume":"148","author":"Ortonne","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2133.1998.02462.x","article-title":"Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid","volume":"139","author":"Tosti","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/1346-8138.13064","article-title":"Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: a randomized, double-blind, placebo-controlled trial","volume":"43","author":"Umezawa","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/09546634.2015.1052036","article-title":"Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomized, left-right comparison study","volume":"27","author":"Muro","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib2085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2230.1985.tb00585.x","article-title":"Comparison of a cream containing 0 1% dithranol in a 17% urea base (Psoradrate\u00ae) with coal tar pomade in the treatment of scalp psoriasis","volume":"10","author":"Wright","year":"1985","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2090","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2133.1971.tb14225.x","article-title":"Psoriasiform napkin dermatitis","volume":"84","author":"Andersen","year":"1971","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2095","first-page":"129","article-title":"Treatment of psoriasic onychodystrophy with a hyaluronic acid product and chondroitinsulphates","volume":"129","author":"Flori","year":"1994","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/095466300300165192","article-title":"Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar\/1% coconut oil\/0.5% salicylic acid (Capasal) shampoo, and long-term experience","volume":"11","author":"McKinnon","year":"2000","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib2105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-4362.1996.tb01641.x","article-title":"Pustular psoriasis limited to the penis","volume":"35","author":"Quan","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2133.1999.02927.x","article-title":"Tacrolimus ointment improves psoriasis in a microplaque assay","volume":"141","author":"Remitz","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1067\/mjd.2003.169","article-title":"Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas","volume":"48","author":"Freeman","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2310\/7750.2008.07055","article-title":"Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis","volume":"12","author":"Bissonnette","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2025.05.010_bib2125","first-page":"334","article-title":"Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques","volume":"5","author":"Mart\u00edn Ezquerra","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2130","first-page":"141","article-title":"Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%","volume":"31","author":"Rallis","year":"2005","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.ad.2025.05.010_bib2135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000321012","article-title":"Psoriatic pseudobalanitis circinata as a post-viral koebner phenomenon","volume":"2","author":"Zampetti","year":"2010","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2140","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1503\/cmaj.180262","article-title":"Psoriasis localized to the glans penis in a 37-year-old man","volume":"190","author":"Yao","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.ad.2025.05.010_bib2145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2133.2003.05426.x","article-title":"Topical tacrolimus for facial psoriasis","volume":"149","author":"Clayton","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2340\/00015555756569","article-title":"Remission of ordinary psoriasis following a short clearance course of cyclosporin","volume":"75","author":"Levell","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000068469","article-title":"Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study","volume":"206","author":"Cannav\u00f2","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib2160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1185\/03007997609109330","article-title":"Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17,21-dipropionate: a double-blind comparison","volume":"4","author":"Lassus","year":"1976","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ad.2025.05.010_bib2165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/030006058201000606","article-title":"Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp","volume":"10","author":"Hillstr\u00f6m","year":"1982","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ad.2025.05.010_bib2170","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/030006058401200306","article-title":"Comparison of topical treatment with desoxymethasone solution 0\u00b725% with salicylic acid 1% and betamethasone valerate solution 0\u00b71% in patients with psoriasis of the scalp","volume":"12","author":"Hillstr\u00f6m","year":"1984","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ad.2025.05.010_bib2175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/09546639009086733","article-title":"A comparative study of betamethasone dipropionate with salicylic acid and betamethasone valerate for the treatment of steroid-responsive dermatoses of the scalp","volume":"1","author":"Curley","year":"1990","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2025.05.010_bib2180","first-page":"254","article-title":"Clinical efficacy of 0.1% tacrolimus onitment on plaque psoriasis of scalp and face","volume":"37","author":"He","year":"2008","journal-title":"J Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2185","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13555-017-0204-3","article-title":"Patients\u2019 perspectives on the impact of genital psoriasis: a qualitative study","volume":"7","author":"Cather","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.05.010_bib2190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000251595","article-title":"The natural history of psoriasis in 5,600 patients","volume":"148","author":"Farber","year":"1974","journal-title":"Dermatologica"},{"key":"10.1016\/j.ad.2025.05.010_bib2195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mjd.2001.110046","article-title":"Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas","volume":"44","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2200","series-title":"Efficacy and safety of calcipotriol plus hydrocortisone ointment compared with tacalcitol ointment in patients with psoriasis on the face and skin folds. Clinicaltrials.gov. NCT00640822","year":"2008"},{"key":"10.1016\/j.ad.2025.05.010_bib2205","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ad.2022.01.006","article-title":"Psoriasis ungueal","volume":"113","author":"Canal-Garc\u00eda","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.010_bib2210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1590\/S0365-05962012000200003","article-title":"Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: Prospective, controlled and randomized pilot study","volume":"87","author":"Nakamura","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000202179","article-title":"Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment","volume":"218","author":"Rigopoulos","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.010_bib2220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00015550252948220","article-title":"Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream","volume":"82","author":"Rigopoulos","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2225","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1111\/jocd.14536","article-title":"Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail psoriasis treatment: a randomized intrapatient left-to-right study","volume":"21","author":"Essa Abd Elazim","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/lsm.22122","article-title":"Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study","volume":"45","author":"Huang","year":"2013","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.ad.2025.05.010_bib2235","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1468-3083.2012.04642.x","article-title":"Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study","volume":"27","author":"De Simone","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2240","first-page":"789","article-title":"Adjuvant role of a new emollient cream in patients with palmar and\/or plantar psoriasis: a pilot randomized open-label study","volume":"145","author":"Cassano","year":"2010","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/0019-5154.77550","article-title":"Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study","volume":"56","author":"Mehta","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1203475417743234","article-title":"A guide to topical vehicle formulations","volume":"22","author":"Mayba","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2025.05.010_bib2255","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101108","article-title":"General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach","volume":"4","author":"Tha\u00e7i","year":"2020","journal-title":"BJGP Open"},{"key":"10.1016\/j.ad.2025.05.010_bib2260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1018975626210","article-title":"Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay","volume":"9","author":"Pershing","year":"1992","journal-title":"Pharm Res"},{"key":"10.1016\/j.ad.2025.05.010_bib2265","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1517\/17425247.2012.711756","article-title":"Topical drug delivery systems in dermatology: a review of patient adherence issues","volume":"9","author":"Tan","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2025.05.010_bib2270","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jaad.2005.04.030","article-title":"Corticosteroids: options in the era of steroid-sparing therapy","volume":"53","author":"Del Rosso","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2275","first-page":"1431","article-title":"Principles and approaches for optimizing therapy with unique topical vehicles","volume":"13","author":"Rosen","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2280","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0738-081X(97)00020-5","article-title":"Corticosteroids","volume":"15","author":"Hughes","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.010_bib2285","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1529-8019.2012.01458.x","article-title":"Conventional topical delivery systems","volume":"24","author":"Weiss","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2025.05.010_bib2290","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2005.01.032","article-title":"Topical drug classification","volume":"295","author":"Buhse","year":"2005","journal-title":"Int J Pharm"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2025.05.010_bib2295","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jaad.2005.04.028","article-title":"A novel foam vehicle for delivery of topical corticosteroids","volume":"53","author":"Huang","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ad.2025.05.010_bib2300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdv.17027","article-title":"Early efficacy and safety data with fixed-dose combination calcipotriol\/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency","volume":"35","author":"Tada","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.010_bib2305","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40257-017-0272-2","article-title":"Development and validation of a novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP)","volume":"18","author":"Teixeira","year":"2017","journal-title":"Am J Clin Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025003709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025003709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:33:14Z","timestamp":1762075994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025003709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":262,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0001731025003709"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.010","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS)","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.065","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}